Tag Archive for: oncology

HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration

/in

Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, has over 12 […]

Read more

Optimum’s chosen charity: Ariana Smiles

/in

In October, at our 15th Annual Healthcare Investor Conference, we announced our chosen charity for the year, Ariana Smiles. Ariana Smiles is a Special Named Fund at the Children’s Cancer and Leukaemia Group, raising funds for research into precision oncology medicine for children with leukaemia. Stephanie Seales Gabbitas and her husband Chris set up Ariana […]

Read more

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference

/in

Data demonstrates METTL1 inhibition in vitro at low nanomolar concentrations while displaying high selectivity over other RNA and protein methyltransferases Data provides the first proof-of-concept that pharmacological inhibition of a tRNA methyltransferase affects tumour growth in vitro and in animal models 8 December 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and […]

Read more

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023

/in

Updated safety and clinical efficacy data presented at leading immuno-oncology conference Exploratory studies suggest roginolisib boosts antitumoral immunity, whilst simultaneously disrupting tumor survival mechanisms Data suggest the potential of radiomics to assess changes in lesions over time, adding value above RECIST (Response Evaluation Criteria in Solid Tumors) Geneva, Switzerland and Amsterdam, The Netherlands, 8 December […]

Read more

Ariceum Therapeutics announces granting of US and Canadian patents for its Gallium-68 radiopharmaceutical production kit

/in

Berlin, Germany, 6 December 2023 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the granting of US and Canadian patents covering its Gallium-68 (Ga-68) radiopharmaceutical production kit. The IP was developed by Theragnostics Ltd, which was acquired by Ariceum earlier […]

Read more